Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.
Michael Rothrock, MBA, MHA: The potential consequences of recurrent or poorly controlled MDD [major depressive disorder] are going to drive potential additional health care resource utilization. That could be cognitive behavioral health, multiple physician visits, or hospitalization rates for those [whose disease is] uncontrolled. There could be development of resistance or lack of adherence because the patient isn’t seeing any benefit, doesn’t feel better, or [can’t] find a reason they need to take the drug. At the end of the day, these consequences are going to lead to poor control and limited improvement in outcomes.
H. Eric Cannon, PharmD, FAMCP: It has been a fascinating journey moving through the coronavirus disease 2019 pandemic. A number of people who were poorly treated to begin with suddenly had access issues getting into their physician. They felt like they were OK. However, in our emergency department, we’ve seen suicide rates and attempted suicides increase and a lot of people turn to self-medicating. The number of overdoses and things have increased at a pretty steep rate. Those consequences are severe, but we also overlook the consequences of what happens within a family. When you have a spouse who’s severely depressed, not getting treatment, or has stopped treatment, there are huge impacts in the basic social structure of their life.
Transcript edited for clarity.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More